Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | K(lysine) acetyltransferase 2A | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | gcn5proteinral control of amino-acid synthesis 5-like 2 gcnl2 | 0.0175 | 1 | 1 |
Toxoplasma gondii | histone lysine acetyltransferase GCN5-A | 0.0051 | 0.0895 | 0.1167 |
Echinococcus granulosus | proteasome prosome macropain | 0.0143 | 0.7664 | 0.7438 |
Trypanosoma cruzi | proteasome subunit beta type-5, putative | 0.0143 | 0.7664 | 1 |
Entamoeba histolytica | proteasome subunit beta type 5 precursor, putative | 0.0143 | 0.7664 | 1 |
Mycobacterium tuberculosis | Proteasome beta subunit PrcB; assembles with alpha subunit PrcA. | 0.0143 | 0.7664 | 0.5 |
Mycobacterium ulcerans | proteasome PrcB | 0.0143 | 0.7664 | 0.5 |
Trichomonas vaginalis | cat eye syndrome critical region protein 2, cscr2, putative | 0.0051 | 0.0895 | 0.1167 |
Plasmodium vivax | histone acetyltransferase GCN5, putative | 0.0051 | 0.0895 | 0.1167 |
Trichomonas vaginalis | Family T1, proteasome beta subunit, threonine peptidase | 0.0143 | 0.7664 | 1 |
Giardia lamblia | Proteasome subunit beta type 5 precursor | 0.0143 | 0.7664 | 1 |
Plasmodium falciparum | histone acetyltransferase GCN5 | 0.0047 | 0.0579 | 0.0755 |
Entamoeba histolytica | acetyltransferase, GNAT family | 0.0047 | 0.0579 | 0.0755 |
Echinococcus granulosus | proteasome subunit beta type 7 | 0.0175 | 0.9995 | 1 |
Mycobacterium leprae | proteasome (beta subunit) PrcB | 0.0143 | 0.7664 | 0.5 |
Loa Loa (eye worm) | acetyltransferase | 0.0175 | 1 | 1 |
Echinococcus multilocularis | gcn5proteinral control of amino acid synthesis | 0.0175 | 1 | 1 |
Echinococcus multilocularis | proteasome subunit beta type 7 | 0.0175 | 0.9995 | 0.9979 |
Echinococcus granulosus | histone acetyltransferase KAT2B | 0.017 | 0.9638 | 0.9608 |
Loa Loa (eye worm) | proteasome A-type and B-type family protein | 0.0143 | 0.7664 | 0.7664 |
Trichomonas vaginalis | bromodomain-containing protein, putative | 0.0051 | 0.0895 | 0.1167 |
Trypanosoma cruzi | proteasome subunit beta type-5, putative | 0.0143 | 0.7664 | 1 |
Schistosoma mansoni | proteasome catalytic subunit 2 (T01 family) | 0.0175 | 0.9995 | 0.9979 |
Trypanosoma brucei | proteasome subunit beta type-5, putative | 0.0143 | 0.7664 | 1 |
Toxoplasma gondii | proteasome subunit beta type, putative | 0.0143 | 0.7664 | 1 |
Plasmodium vivax | proteasome subunit beta type-5, putative | 0.0143 | 0.7664 | 1 |
Giardia lamblia | Histone acetyltransferase GCN5 | 0.0047 | 0.0579 | 0.0755 |
Brugia malayi | Proteasome A-type and B-type family protein | 0.0175 | 0.9995 | 0.9979 |
Plasmodium falciparum | proteasome subunit beta type-5 | 0.0143 | 0.7664 | 1 |
Toxoplasma gondii | histone lysine acetyltransferase GCN5-B | 0.0051 | 0.0895 | 0.1167 |
Leishmania major | proteasome beta 5 subunit, putative | 0.0143 | 0.7664 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.3162 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of GCN5L2. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504398] | ChEMBL. | No reference |
Potency (functional) | = 70.7946 um | PUBCHEM_BIOASSAY: qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins. (Class of assay: confirmatory) [Related pubchem assays: 1011 (Confirmation Concentration-Response Assay for Inhibitors of the Schistosoma mansoni Redox Cascade ), 448 (Schistosoma Mansoni Peroxiredoxins (Prx2) and thioredoxin glutathione reductase (TGR) coupled assay)] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.